

Date 13/03/2026
Your Ref
Our Ref 11168

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – RENAL CELL CARCINOMA PRESCRIBING

I write in response to your request for information in relation to renal cell carcinoma prescribing.

Question:

1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- Avelumab + Axitinib
- Axitinib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Lenvatinib + Pembrolizumab
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

Answer:

- Avelumab + Axitinib 0
- Axitinib 9
- Cabozantinib 24
- Everolimus 0

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
*Lothian NHS Board is the common
name of Lothian Health Board*

- Lenvatinib + Everolimus 7
- Lenvatinib + Pembrolizumab 5 or fewer
- Nivolumab monotherapy 5 or fewer
- Nivolumab + Cabozantinib 18
- Nivolumab + Ipilimumab 5 or fewer
- Pazopanib 6
- Pembrolizumab monotherapy 13
- Pembrolizumab + Axitinib 5 or fewer
- Radiotherapy only unavailable – requires linkage*
- Sunitinib 5 or fewer
- Temsirolimus 0
- Tivozanib 0
- Other active systemic anti-cancer therapy 0
- Palliative care only unavailable – requires linkage*

Question:

2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta)
- Cabozantinib (Cometriq)
- Nivolumab (Opdivo)
- Nivolumab + Cabozantinib (Opdivo + Cometriq)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)

Answer:

- Avelumab + Axitinib (Bavencio + Inlyta) 0
- Cabozantinib (Cometriq) 9
- Nivolumab (Opdivo) 0
- Nivolumab + Cabozantinib (Opdivo + Cometriq) 21
- Nivolumab + Ipilimumab (Opdivo + Yervoy) 9
- Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) 5 or fewer

Question:

3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib
- Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)

- Cabozantinib (Cometriq)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Answer:

- Nivolumab (monotherapy) 7
- Nivolumab + Ipilimumab 8
- Nivolumab + Cabozantinib 25
- Avelumab + Axitinib 0
- Lenvatinib + Pembrolizumab (Kispalyx + Keytruda) 5 or fewer
- Cabozantinib (Cometriq) 26

Question:

4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Answer:

There were 50.

Question:

5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Answer:

Full Title	Recruited
WIRE, Window-of-opportunity clinical trial platform for evaluation of novel treatment strategies in renal cell cancer	8
ModiFY, A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer	8

* This information is not held in a centrally extractable format. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients and prescribing over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records,

the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive